间充质干细胞和间充质干细胞衍生的外泌体:一种治疗视网膜退行性疾病的有前景的策略。
Mesenchymal stem cells and mesenchymal stem cell-derived exosomes: a promising strategy for treating retinal degenerative diseases.
作者信息
An Wenjing, Zhang Wenliang, Qi Jia, Xu Weihui, Long Yushan, Qin Huan, Yao Kai
机构信息
Institute of Visual Neuroscience and Stem Cell Engineering, Wuhan University of Science and Technology, Wuhan, 430065, China.
College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan, 430065, China.
出版信息
Mol Med. 2025 Feb 21;31(1):75. doi: 10.1186/s10020-025-01120-w.
Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy in regenerative medicine, demonstrating significant potential for clinical applications. Evidence suggests that MSCs not only exhibit multipotent differentiation potential but also exert critical therapeutic effects in retinal degenerative diseases via robust paracrine mechanisms. MSCs protect retinal cells from degenerative damage by modulating inflammation, inhibiting apoptosis, alleviating oxidative stress, and suppressing cell death pathways. Furthermore, MSCs contribute to retinal structural and functional stability by facilitating vascular remodeling and donating mitochondria to retinal cells. Of particular interest, MSC-derived exosomes have gained widespread attention as a compelling cell-free therapy. Owing to their potent anti-inflammatory, anti-apoptotic, and vascular-stabilizing properties, exosomes show significant promise for the treatment of retinal degenerative diseases.
间充质干细胞(MSCs)已成为再生医学中一种很有前景的治疗策略,显示出巨大的临床应用潜力。有证据表明,MSCs不仅具有多能分化潜力,还通过强大的旁分泌机制在视网膜退行性疾病中发挥关键的治疗作用。MSCs通过调节炎症、抑制细胞凋亡、减轻氧化应激和抑制细胞死亡途径来保护视网膜细胞免受退行性损伤。此外,MSCs通过促进血管重塑和向视网膜细胞捐赠线粒体,有助于维持视网膜的结构和功能稳定。特别值得关注的是,源自MSCs的外泌体作为一种引人注目的无细胞疗法已受到广泛关注。由于其强大的抗炎、抗凋亡和血管稳定特性,外泌体在治疗视网膜退行性疾病方面显示出巨大的前景。